Pharmafile Logo
Pharmafocus logo
Advanced Search

Tradjenta

Showing 8 posts of 8 posts found.

Lilly and Boehringer diabetes drug sees US launch

March 24, 2015
Sales and Marketing Boehringer, Glyxambi, Tradjenta, diabetes, empagliflozin/linagliptin, lilly, linagliptin

Lilly and Boehringer Ingelheim’s combo diabetes drug Glyxambi is now available to treat adult patients in the US. Glyxambi (empagliflozin/linagliptin) …

News
Glyxambi image

Boehringer and Lilly score FDA yes for Glyxambi

February 3, 2015
Sales and Marketing Boehringer, FDA, Glyxambi, Tradjenta, empagliflozin, jardiance, lilly, linagliptin

The FDA has approved Glyxambi (empagliflozin/linagliptin), which has become the first combination of two diabetes drugs in their different classes …

News

Boehringer hands back Lilly drug

January 8, 2013
Research and Development, Sales and Marketing Boehringer, Tradjenta, diabetes, lilly

Boehringer Ingelheim has handed back one of Eli Lilly’s investigational diabetes drugs as a result of ‘independent strategic portfolio considerations’. …

News
Boehringer-Lilly's Trajenta

Boehringer-Lilly won’t launch Trajenta in Germany

September 5, 2011
Sales and Marketing Drug pricing, Germany, Tradjenta, Trajenta, price cuts

Boehringer Ingelheim and Lilly have decided not to launch their new diabetes drug Trajenta in Germany and say the country’s …

News
Boehringer - Lilly's Trajenta (linagliptin)

Boehringer-Lilly’s Trajenta wins European approval

August 26, 2011
Sales and Marketing Tradjenta, Trajenta, diabetes

Boehringer Ingelheim and Eli Lilly’s new type II diabetes drug Trajenta has been approved Europe. The European Commission backed Trajenta …

News
Boehringer Ingelheim Eli Lilly Trajenta linagliptin

CHMP backs Boehringer-Lilly diabetes drug Trajenta

June 27, 2011
Sales and Marketing Tradjenta, Trajenta, diabetes

Boehringer Ingelheim and Eli Lilly’s new type II diabetes drug Trajenta has been recommended for European approval. It was given …

News
Boehringer Ingelheim and Lilly's diabetes drug Tradjenta

Boehringer-Lilly launch diabetes drug Tradjenta in US

June 16, 2011
Sales and Marketing Boehringer Ingelheim, Tradjenta, diabetes, lilly

Boehringer Ingelheim and Eli Lilly’s new type II diabetes treatment Tradjenta has been launched in the US. Tradjenta (linagliptin) is …

News

US approval for Boehringer’s diabetes drug Tradjenta

May 3, 2011
Sales and Marketing Boehringer Ingelheim, Tradjenta, diabetes, lilly

Tradjenta, the once-daily oral type II diabetes treatment developed by Boehringer Ingelheim, has been approved by US regulators. The FDA …

News
The Gateway to Local Adoption Series

Latest content

Siemens Healthineers opens 10m euro R&D centre for laboratory equipment in Ireland

February 19, 2026

Everdrone announces new board of directors to drive expansion

February 19, 2026

Regeneron announces presentations of new data on Eylea HD for retinal disease

February 18, 2026

Indegene completes acquisition of Cake Health

February 18, 2026

Gedeon Richter UK acquires rights to schizophrenia treatment Reagila from Recordati Pharmaceuticals

February 17, 2026